This study is an open-label, multi-center Phase II clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate and platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer.

Inclusion Criteria:

1. Female aged 18-75 years.
2. Histopathologically confirmed recurrent/metastatic cervical squamous cell carcinoma, adenocarcinoma or adenosquamous cell carcinoma that cannot be radically treated by surgery, radiotherapy or chemoradiotherapy.
3. No prior systemic anti-cancer therapy for recurrent/metastatic disease.
4. According to RECIST v1.1 criteria, the patient must have at least one measurable lesion.
5. Able to normally swallow drug tablets
6. Has adequate organ function.
7. Willing to participate and able to comply with research programme requirements.
8. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
9. Estimated life expectancy of more than 3 months.

Exclusion Criteria:

1. Has any malignancy <5 years prior to study entry.
2. Known to have brain or meningeal metastasis.
3. Known to have autoimmune disease.
4. Received live vaccinations 4 weeks before randomization or during the study period.
5. Known allergies and contraindications to the investigational drug or any of its components.